Watchlist Price Alert

GeneDx Corp. (WGS)

NASDAQ: WGS · Real-Time Price · USD

64.58

-1.79 (-2.70%)

At close: Jun 13, 2025, 3:59 PM

64.30

-0.43%

After-hours: Jun 13, 2025, 05:59 PM EDT

-2.70% (1D)

Bid	63.8
Market Cap	1.84B
Revenue (ttm)	330.14M
Net Income (ttm)	-38.58M
EPS (ttm)	-1.4
PE Ratio (ttm)	-46.13
Forward PE	34.68
Analyst	Strong Buy

Ask	66.04
Volume	435,480
Avg. Volume (20D)	1,089,690
Open	64.68
Previous Close	66.37
Day's Range	63.48 - 65.95
52-Week Range	24.91 - 117.75
Beta	2.01

About WGS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol WGS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for WGS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

-42.85%

GeneDx Holdings shares are trading lower. The comp... Unlock content with Pro Subscription

3 months ago

+4.93%

GeneDx Holdings shares are trading higher after the company announced an indication expansion for its industry leading genetic testing to now include cerebral palsy.

News

2 days ago · businesswire.com

Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation – WGS

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ:...

3 days ago · businesswire.com

WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law Firm.

2 weeks ago · zacks.com

Wall Street Analysts Predict a 32.62% Upside in GENEDX HOLDINGS (WGS): Here's What You Should Know

The consensus price target hints at a 32.6% upside potential for GENEDX HOLDINGS (WGS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings es...

3 weeks ago · businesswire.com

GeneDx to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that company management will participate in upcoming investor conferences.

3 weeks ago · businesswire.com

GeneDx Publishes Pioneering Vision for Applying AI to Genomics to Improve and Expedite Diagnosis of Genetic Disease at Scale

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced the publication of a new article demonstrating the company's leadership in applying AI to accelerate and enhance genetic diagnostics.

3 weeks ago · seekingalpha.com

GeneDx: Strong Fundamentals Intact As Market Misreads Test Volume Dip

GeneDx delivered strong Q1 2025 results, beating revenue and EPS estimates, and raised full-year guidance despite a minor sequential test volume dip. The volume decline is attributable to seasonality,...

1 month ago · seekingalpha.com

GeneDx: Time To Buy The Dip

GeneDx's recent 50% stock drop post-Q1 earnings is seen as an overreaction, despite a projected modest growth slowdown from 42% to 30-35%. The company is expanding product lines, improving margins, an...

1 month ago · businesswire.com

GeneDx Announces Completion of Fabric Genomics Acquisition

GAITHERSBURG, Md. & OAKLAND, Calif.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced the successful completion of its acquisition of Fabric Genomics, a pioneer in AI-powered genomic interpretati...